

Promising gene therapy for cancer

The USA Food and Drug Administration has approved Vitrakvi (larotrectinib), which was co-developed by Bayer and Loxo Oncology. It is the first drug developed to treat cancer with a specific genetic characteristic regardless of its location in the body.